Actuate Therapeutics: Poised for Potential $200M+ Pediatric Priority Review Vouchers and Transformative Combinations in RAS-Driven Cancers

Rhea-AI Summary

Actuate Therapeutics (NASDAQ:ACTU) reported encouraging pediatric and formulation progress for elraglusib, a selective GSK-3β inhibitor, including phase 1 pediatric responses and an oral formulation with ~51% bioavailability versus IV.

Key catalysts: pediatric complete responses supporting Ewing sarcoma and neuroblastoma development, eligibility for a Rare Pediatric Disease Priority Review Voucher, planned adult oral and RAS-combination programs, and potential PRV monetization worth $150–$205M based on recent market transactions.

Positive

• 3 pediatric complete responses in 40-patient phase 1 trial
• Oral bioavailability ~51% relative to IV when dosed with food
• PRV monetization potential with recent vouchers selling for $150–$205M
• Planned RAS combination data expected in H2 2026

Negative

• Pediatric data are early-stage: 40 patients total in Actuate-1902
• Oral exposure is ~51% vs IV, which may affect dosing strategies
• Preclinical RAS combination readouts are pending, delaying partnership clarity

News Market Reaction – ACTU

-9.43%

8 alerts

-9.43% News Effect

-14.2% Trough in 3 hr 56 min

-$6M Valuation Impact

$59M Market Cap

0.9x Rel. Volume

On the day this news was published, ACTU declined 9.43%, reflecting a notable negative market reaction. Argus tracked a trough of -14.2% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $6M from the company's valuation, bringing the market cap to $59M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Oral bioavailability: 51% Pediatric trial size: 40 children and adolescents Ewing sarcoma responses: 2 complete responses +5 more

8 metrics

Oral bioavailability 51% Elraglusib oral formulation vs IV, dosed with food in healthy volunteers

Pediatric trial size 40 children and adolescents Actuate-1902 Phase 1 trial in relapsed/refractory malignancies (ages 3–21)

Ewing sarcoma responses 2 complete responses Relapsed/refractory metastatic Ewing sarcoma with elraglusib plus cyclophosphamide/topotecan

Neuroblastoma response 1 complete response Relapsed/refractory metastatic neuroblastoma with elraglusib combination therapy

PRV sale price $200 million Jazz Pharmaceuticals voucher sale in January 2026 cited as benchmark

PRV sale price $205 million Fortress Biotech voucher sale in February 2026

PRV sale price $155 million Abeona Therapeutics voucher sale in June 2025

RAS mutation prevalence 30% of all human cancers Estimated share of cancers driven by RAS mutations mentioned in article

Market Reality Check

Price: $2.21 Vol: Volume 40,416 vs 20‑day a...

low vol

$2.21 Last Close

Volume Volume 40,416 vs 20‑day average 87,017 ahead of this article, indicating subdued trading interest. low

Technical Shares at $2.44 are well below the $6.36 200‑day MA and 79.65% below the 52‑week high.

Peers on Argus

ACTU was up 3.83% while peers showed mixed moves: AVTX +0.60%, GLSI +0.84%, but ...

ACTU was up 3.83% while peers showed mixed moves: AVTX +0.60%, GLSI +0.84%, but CRDF -4.81%, NVCT -2.02%, ONCY -2.15%, suggesting a stock‑specific bias rather than a clean sector rotation.

Historical Context

5 past events · Latest: Mar 09 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 09	RAS combo initiative	Positive	+3.0%	Launched expanded research program combining elraglusib with RAS‑targeted therapies.
Mar 04	Conference presentation	Neutral	+4.9%	Announced CEO presentation and meetings at Citizens Life Sciences conference.
Feb 24	Conference appearance	Neutral	+10.6%	Disclosed CEO presentation and investor meetings at Oppenheimer healthcare conference.
Jan 21	Oral tablet program	Positive	+5.4%	Planned Phase 1/2 program for oral elraglusib in advanced cancers with survival data support.
Jan 12	Phase 2 PDAC data	Positive	-6.3%	Phase 2 trial showed OS benefit with elraglusib plus GnP in metastatic pancreatic cancer.

Pattern Detected

Recent news, especially clinical and event‑driven updates, has often coincided with positive 1‑day moves, though strong pancreatic data once saw a negative reaction.

Recent Company History

Over the past several months, Actuate has highlighted elraglusib’s progress across conferences and clinical updates. A Jan 12, 2026 ASCO GI presentation showed improved survival in metastatic pancreatic cancer yet the stock fell 6.35%. Subsequent clinical pipeline expansion for the oral tablet on Jan 21 and multiple conference presentations in February–March were followed by 1‑day gains between 4.92% and 10.64%. The March RAS‑combination initiative also saw a positive reaction. Today’s broader narrative on PRVs, pediatrics and combinations fits this arc of positioning elraglusib as a multi‑indication asset.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2025-09-02

An effective Form S-3 shelf filed on Sep 2, 2025 allows ACTU to offer various securities (common stock, debt, warrants, units) via future prospectus supplements through Sep 2, 2028. The shelf has been tapped at least 2 times via 424B5 offerings, giving the company pre‑cleared flexibility to raise additional capital.

Market Pulse Summary

The stock moved -9.4% in the session following this news. A negative reaction despite upbeat discuss...

Analysis

The stock moved -9.4% in the session following this news. A negative reaction despite upbeat discussion of PRVs, pediatric data and RAS combinations would fit past divergence, such as the -6.35% move on positive Phase 2 pancreatic data. With shares already well below the $6.36 200‑day MA and 79.65% under the 52‑week high pre‑article, sentiment had been fragile. The existing S-3 shelf and prior equity offerings highlighted in filings provide additional context for how the market has weighed dilution and funding risks against clinical progress.

Key Terms

glycogen synthase kinase-3 beta, GSK-3β, rare pediatric disease designation, priority review voucher, +4 more

8 terms

glycogen synthase kinase-3 beta medical

"elraglusib, a first-in-class, highly selective small-molecule inhibitor of glycogen synthase kinase-3 beta"

Glycogen synthase kinase-3 beta is a cellular enzyme that acts like a molecular switch, turning other proteins on or off by adding small chemical tags; it helps control processes such as cell survival, metabolism and memory-related pathways. Investors watch it because drugs that block or modify this enzyme are a common target for treatments in areas like neurodegeneration, diabetes and cancer, and progress or setbacks in that research can materially affect the value and risk of companies developing such therapies.

GSK-3β medical

"inhibitor of glycogen synthase kinase-3 beta (GSK-3β). This multimodal agent targets tumor survival"

GSK-3β is an enzyme inside cells that acts like a molecular switch, helping control processes such as cell growth, survival and response to signals. Investors pay attention because drugs that change this enzyme’s activity are being explored for conditions like neurodegenerative diseases, mood disorders and cancer, so clinical results or regulatory decisions targeting GSK-3β can materially affect a company’s drug pipeline value and risk profile.

rare pediatric disease designation regulatory

"the FDA first granted Rare Pediatric Disease Designation to elraglusib for neuroblastoma"

A rare pediatric disease designation is an official regulatory status given to a drug or therapy that targets a serious or life‑threatening condition primarily affecting children and is uncommon in the population. It matters to investors because the status often brings financial and development perks — such as tax credits, reduced fees, faster review and periods of market protection — which can lower costs, speed approval and improve the commercial outlook; think of it as a VIP pass that makes bringing a scarce, child‑focused treatment to market easier and potentially more profitable.

priority review voucher regulatory

"would be eligible to receive a Priority Review Voucher (PRV). The PRV program incentivizes"

A priority review voucher is a transferable regulatory incentive that lets a company move a future drug or device application to the front of the review line, shortening the review period by several months. For investors it matters because the voucher can speed up market access for a high-value product or be sold to other companies for significant cash, acting like a tradable fast-pass that can accelerate revenue or create immediate financial upside.

new drug application regulatory

"Upon approval of a New Drug Application for either indication, Actuate would be eligible"

A new drug application is a formal request submitted to government regulators seeking approval to market a new medicine. It is like a detailed proposal that shows the drug has been tested for safety and effectiveness. For investors, receiving approval signals that the drug may soon become available for sale, potentially leading to revenue growth and impacting the company's value.

NF-κB signaling medical

"targets tumor survival pathways, DNA damage response, NF-κB signaling and the tumor immune"

NF-κB signaling is a cellular communication pathway that turns on genes controlling inflammation, immune responses and cell survival when tissues face stress or infection; think of it as a switchboard that tells cells how urgently to react. Investors care because overactive or blocked NF-κB can drive diseases (like chronic inflammation and some cancers), making it a common drug target; therapies or safety findings tied to this pathway can materially affect clinical results, regulatory chances and company value.

DNA damage response medical

"targets tumor survival pathways, DNA damage response, NF-κB signaling and the tumor immune"

A DNA damage response is the set of cellular systems that detect and repair breaks or errors in a cell’s genetic material; think of it as a repair crew and alarm system that keeps DNA functioning properly. It matters to investors because drugs that enhance, inhibit, or exploit these repair pathways can change a therapy’s effectiveness, safety, market potential and regulatory risk, affecting the value of biotech and pharmaceutical companies.

phase 1 medical

"successfully completed a phase 1 study of elraglusib oral formulation in healthy volunteers"

Phase 1 is the first stage of testing a new drug or medical treatment in people, focused primarily on safety, how the body handles the product, and finding a tolerated dose. Think of it as a short, tightly controlled experiment with a small group to check for dangerous side effects before wider testing; for investors it is an early milestone that reduces some uncertainty but still carries high risk and potential for both big value changes and setbacks.

AI-generated analysis. Not financial advice.

Meg Flippin, Benzinga Staff Writer

CHICAGO, IL AND FORT WORTH, TX / ACCESS Newswire / March 24, 2026 / Actuate Therapeutics, Inc. (NASDAQ:ACTU) is a clinical-stage biopharmaceutical company advancing elraglusib, a first-in-class, highly selective small-molecule inhibitor of glycogen synthase kinase-3 beta (GSK-3β). This multimodal agent targets tumor survival pathways, DNA damage response, NF-κB signaling and the tumor immune microenvironment, offering a new potential treatment across multiple difficult-to-treat cancers including metastatic pancreatic ductal adenocarcinoma (mPDAC), melanoma, colorectal cancer and sarcomas.

What sets Actuate apart is its dual formulation strategy and recent momentum in pediatrics. While the company reports that the intravenous (IV) form has generated compelling clinical data, it is also advancing an oral tablet version of elraglusib that could significantly expand the drug's utility and commercial appeal.

The Oral Compound: Convenience, Compliance And Broader Reach

Actuate has successfully completed a phase 1 study of elraglusib oral formulation in healthy volunteers, demonstrating robust bioavailability-approximately 51% relative to IV when dosed with food-and dose-proportional pharmacokinetics without unexpected safety signals. A Phase 1 dose-escalation trial of the oral tablet in advanced cancer patients (Actuate-2401) is planned, with the oral formulation offering key advantages: daily dosing for steady-state exposure, improved patient compliance (especially in long-duration responses), lower manufacturing costs at commercial scale and potential expansion into pediatric populations or adult indications where oral therapies are preferred.

This shift to oral could broaden elraglusib's addressable market while maintaining the same potent GSK-3β inhibition that has already shown disease control and responses when combined with chemotherapy backbones.

Pediatric Breakthroughs And The Rare Pediatric Disease Priority Review Voucher (PRV)

In January 2026, Actuate reported highly encouraging phase 1 data from the open-label Actuate-1902 trial in 40 children and adolescents (ages 3-21) with relapsed/refractory malignancies. Notable highlights included two complete responses in relapsed/refractory metastatic Ewing sarcoma and one complete response in relapsed/refractory metastatic neuroblastoma when elraglusib was combined with cyclophosphamide/topotecan. No maximum tolerated dose was reached, and responses supported plans to advance into Ewing sarcoma (and potentially neuroblastoma) in 2026.

Crucially, the FDA first granted Rare Pediatric Disease Designation to elraglusib for neuroblastoma and subsequently for Ewing sarcoma in November 2024. Upon approval of a New Drug Application for either indication, Actuate would be eligible to receive a Priority Review Voucher (PRV).

The PRV program incentivizes development for rare pediatric diseases (affecting fewer than 200,000 U.S. children) by granting the sponsor a voucher redeemable for a six-month priority FDA review of any future marketing application-potentially shaving four months off the standard 10-month timeline. Vouchers are fully transferable and can be sold to other companies, providing a non-dilutive financing mechanism that has historically delivered substantial value.

The High Value Of Pediatric Review Vouchers And Recent Sales

Actuate reports that PRVs have traded at premium prices in recent years, reflecting their ability to accelerate revenue for blockbuster candidates. Following the program's reauthorization through September 2029 via the Consolidated Appropriations Act of 2026, transaction values have remained strong:

• Jazz Pharmaceuticals sold a voucher for $200 million (January 2026)

• Fortress Biotech reportedly sold one for $205 million (February 2026)

• Abeona Therapeutics: $155 million (June 2025)

• Zevra Therapeutics: $150 million (April 2025)

• Ipsen: $158 million (August 2024)

• Acadia Pharmaceuticals and PTC Therapeutics: $150 million each (late 2024)

Average recent sales have clustered around $150-200 million, with some exceeding that level. For a small-cap company like Actuate, monetizing a PRV could represent transformative non-dilutive capital to fund late-stage development, oral formulation advancement or strategic partnerships-without relying solely on equity raises or debt.

Why RAS Inhibitor Leaders Like Revolution Medicines (RVMD) And Erasca (ERAS) May Need To Combine With Elraglusib

RAS mutations drive ~30% of all human cancers, including the majority of pancreatic, colorectal and certain lung cancers-areas where single-agent RAS(ON) or RAS pathway inhibitors have shown promise but face adaptive resistance. In March 2026, Actuate launched a dedicated research initiative evaluating elraglusib in combination with emerging RAS-targeted therapies. Preclinical combination data are expected in the second half of 2026.

The scientific rationale is compelling and multi-pronged, reports Actuate. Elraglusib's GSK-3β inhibition disrupts downstream survival signaling (via NF-κB and MYC suppression), impairs DNA damage repair and enhances anti-tumor immunity by boosting antigen presentation and activating T- and NK-cell responses. When paired with RAS(ON) inhibitors-which potently block proliferative RAS-GTP signaling-the combination can push tumor cells past the apoptotic threshold and overcome resistance mechanisms that limit monotherapy durability.

Revolution Medicines (RVMD) is advancing a leading RAS(ON) portfolio, including the multi-selective inhibitor daraxonrasib (RMC-6236), G12C-selective elironrasib and G12D-selective zoldonrasib, with strong focus on KRAS-mutant pancreatic ductal adenocarcinoma (PDAC), NSCLC and colorectal cancer. Erasca (ERAS) is similarly pursuing RAS/MAPK pathway inhibitors. Both companies' assets excel at shutting down oncogenic RAS signaling but may benefit from orthogonal mechanisms like GSK-3β blockade to address tumor intrinsic resistance, immune evasion and microenvironment support.

Actuate's initiative positions elraglusib as a natural complementary agent. In RAS-addicted tumors, the combination strategy could deliver deeper, more durable responses - potentially expanding the clinical and commercial opportunity for RVMD, ERAS and other RAS-focused players while creating high-value partnership or licensing opportunities for Actuate.

Outlook: Multiple Catalysts And Strategic Optionality

With positive pediatric data, an advancing oral formulation, mPDAC phase 2 overall survival signals and a new RAS combination program, Actuate is entering a high-impact period. A potential PRV monetization upon pediatric approvals could provide immediate capital, while the oral program and RAS research initiative open doors to broader adult oncology markets and collaborations.

As the only clinical-stage GSK-3β inhibitor with this breadth of mechanistic and clinical support, Actuate believes elraglusib could become a backbone therapy in both rare pediatric cancers and the much larger RAS-mutant solid tumor landscape. For investors and patients alike, Actuate Therapeutics may deserve a closer look as a rather compelling case where scientific innovation, regulatory incentives and strategic positioning converge.

Click here for more information on Actuate Therapeutics.

Featured image from Shutterstock.

This post contains sponsored content and was created in collaboration with a third-party partner. Benzinga is a publisher and does not provide personalized investment advice or act as a broker or dealer. This content is for informational purposes only and is not intended to be investing advice or an offer or solicitation to buy or sell any security.

Contact:
Investor Relations
info@actuatetherapeutics.com

SOURCE: Actuate Therapeutics, Inc.

View the original press release on ACCESS Newswire

FAQ

What pediatric results did Actuate (ACTU) report on March 24, 2026?

Actuate reported two complete responses in Ewing sarcoma and one in neuroblastoma among 40 children and adolescents. According to Actuate, these responses occurred in the Actuate-1902 trial and support planned studies in 2026.

How much oral bioavailability did Actuate report for elraglusib (ACTU)?

The company reported ~51% oral bioavailability relative to IV when dosed with food, with dose-proportional pharmacokinetics. According to Actuate, the oral tablet completed a healthy-volunteer phase 1 study showing no unexpected safety signals.

What is a Priority Review Voucher and how could it help Actuate (ACTU)?

A PRV grants a six-month FDA priority review transferable to other applications, shortening review time by ~4 months. According to Actuate, approval in a pediatric indication could make elraglusib eligible for a valuable, sellable PRV.

What recent PRV sale prices suggest for Actuate (ACTU) value prospects?

Recent PRV transactions have ranged from $150M to $205M, with Jazz at $200M and Fortress at $205M. According to Actuate, similar voucher sales illustrate potential non-dilutive capital if a PRV is obtained.

When will Actuate (ACTU) release preclinical RAS combination data for elraglusib?

Actuate expects preclinical combination data in the second half of 2026. According to Actuate, these results will inform potential combinations with RAS-targeted therapies and partnership opportunities.